NextCell Pharma AB
Lindsay Davies is a highly experienced professional in the fields of cell and gene therapy, stem cell immunology, and medical device development. As Co-Founder of QVance and Chief Executive Officer and Founder of CellTherEx Consulting, Lindsay has a strong entrepreneurial background. In current roles as European Regional Secretary for the International Society for Cell & Gene Therapy and Chief Scientific Officer at NextCell Pharma AB, responsibilities include leadership and strategic direction in the development of innovative therapies. Lindsay's tenure at Karolinska Institutet spans from researcher to affiliated researcher, contributing significantly to academic knowledge, including work on oral mucosal lamina propria progenitor cells. Previous experience includes a position as a Medical Device Development Specialist at Finnish Red Cross Blood Service and various research roles at Cardiff University, culminating in a PhD in Orthopaedic Biochemistry. Education includes fellow status with The Higher Education Academy and extensive research experience related to progenitor cells and their therapeutic applications.
This person is not in any teams
NextCell Pharma AB
NextCell Pharma is an innovative Biotech growing out of the need for Advanced Therapy Medicinal Products for Autoimmune Disease and Transplantation. Cellaviva, the first Swedish family saving stem cell bank, with its expertise in umbilical cord stem cells and Diamyd Medical with its interests and investments within autoimmune diseases made a natural partnership for creating NextCell Pharma. Clinical trials testing NextCell Pharma’s first product, ProTrans,has started in Novermber 2018. #nextcellpharma #cellaviva